Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study-Reference-Cited by-同舟云学术

Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study

Published:2015-01-21 Issue:2 Volume:95 Page:160-167
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Durot Eric¹²,Michallet Anne-Sophie³,Leprêtre Stéphane⁴,Le Quoc-Hung¹,Leblond Véronique⁵⁶,Delmer Alain¹²

Affiliation:

1. Service d'Hématologie Clinique; Centre Hospitalier Universitaire; Hôpital Robert Debré; Reims France

2. UFR Médecine; Université Reims Champagne-Ardenne; Reims France

3. Service d'Hématologie Clinique; Centre Hospitalier Lyon Sud; Pierre Bénite France

4. Département d'Hématologie, Unicancer; Centre Henri Becquerel; Rouen France

5. AP-HP; Service d'Hématologie Clinique; Hôpital Pitié-Salpêtrière; Paris France

6. UPMC Université Paris 06 GRC11-GRECHY; Paris France

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12474/fullpdf

Reference41 articles.

1. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

2. Risk categories and refractory CLL in the era of chemoimmunotherapy;Zenz;Blood,2012

3. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus;Dreger;Leukemia,2007

4. Richter's syndrome: a report on 39 patients;Robertson;J Clin Oncol,1993

5. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome;Dabaja;Leuk Lymphoma,2001

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial;The Lancet Oncology;2024-09

2. SOHO State of the Art Updates and Next Questions | Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions;Clinical Lymphoma Myeloma and Leukemia;2024-07

3. Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience;Annals of Hematology;2024-01-22

4. Richter's transformation: Transforming the clinical landscape;Blood Reviews;2023-12

5. SOHO State of the Art Updates and Next Questions | Treatment of Richter's Transformation;Clinical Lymphoma Myeloma and Leukemia;2023-11